The Valley Hospital participates in global cardiac clinical trial.


Byline: Jessica Perry

The Valley Hospital in Ridgewood announced on Monday it participated in a landmark clinical trial that evaluated the ability of a new, fully absorbable antibacterial envelope TYRX Absorbable Antibacterial Envelope from Medtronic designed to reduce infections associated with cardiac implantable electronic devices (CIEDs).

The TYRX Absorbable Antibacterial Envelope is a mesh envelope that holds an implantable cardiac device or implantable neurostimulator.

In a press release, the hospital said that the study found positive results and demonstrated that the envelope reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, in patients at increased risk for infections receiving CIEDs, compared to standard-of-care pre-operative antibiotics.

The trial results were recently presented in a late-breaking session at the American College of Cardiology's 68th Annual Scientific Sessions and published in The New England Journal of Medicine.

The trial met its primary objective, showing effectiveness of the TYRX envelope in reducing major infections by 40 percent and reducing pocket infections by 61 percent in patients at increased risk for infections resulting from CIED implantation. The trial also met its safety objective: the envelope did not...

To continue reading